Qu Biologics Completes Enrolment of a Unique Study Testing a Novel Immunomodulator to Restore Immune Function in the Elderly
QBKPN SSI is designed to restore and enhance innate immune function, the body's first line of defense against infections and other diseases such as cancer. As we age, our innate immune function declines, leaving us vulnerable to not only infectious threats, as was seen during the COVID-19 pandemic, but also to the development of chronic inflammatory diseases, metabolic disease, and cancer. The RESILIENCE Study is assessing if QBKPN treatment can restore innate immune function in the elderly, with important implications for improving response to immunological threats, including cancer and other chronic diseases, and improving all-cause mortality.
Dr. Hal Gunn, CEO of Qu Biologics, stated, 'Completing enrolment of a clinical study is an exciting milestone, particularly in this case, since there are no current treatments that prevent the decline in immune function that occurs with aging. This age-related immune decline is the largest unmet need in healthcare since it increases the risk of pre-mature aging, infections, inflammatory diseases, and cancer. Positive results from our RESILIENCE Study would have very important implications for extending healthy longevity.' Immunologist Dr. Shirin Kalyan, Qu's VP of Scientific Innovation, stated, 'We have previously demonstrated in proof-of-concept studies that QBKPN treatment can reverse immune dysregulation that occurs with aging, inflammatory diseases, and cancer to improve health outcomes. Qu's SSIs are designed, not just to treat disease, but to restore health and clear important underlying causes of disease – a fundamentally different way of thinking about the treatment of disease and what medicines could be.'
In advance of the results from the RESILENCE Study, Qu Biologics is completing a USD $2M bridge round and is reaching out to Pharma partners for co-development. Interested parties are welcome to contact Dr. Hal Gunn, CEO, at investor.relations@qubiologics.com.
For more information about Qu Biologics and the science behind SSIs, please visit www.qubiologics.com.
About Qu BiologicsQu Biologics is a clinical stage biotechnology company developing Site Specific Immunomodulators (SSI), a novel class of immunomodulators designed to restore innate immune function in targeted organs to reverse the immune dysregulation underlying many important diseases including cancer, chronic inflammatory diseases, metabolic disease, and infection. Qu Biologics has completed four Phase 2 studies in lung cancer, Crohn's disease, and ulcerative colitis. Two additional Phase 2 randomized placebo-controlled studies, in late-stage colon cancer and immunosenescence, are underway.
Backed by a prestigious group of scientific advisors and board members, Qu Biologics is led by a management team that includes co-founder and CEO Dr. Hal Gunn, a physician and expert on the body's immune response to chronic disease; Chief Medical Officer - Oncology Dr. Simon Sutcliffe, former CEO of the BC Cancer Agency and a distinguished clinician, scientist and leader in cancer control in Canada and internationally; and Chief Medical Officer – Infectious Disease Dr. Ted Steiner, a clinician-scientist specializing in immune responses to infections and Head of the University of British Columbia Division of Infectious Diseases. For more information, please visit www.qubiologics.com.
For more information regarding this press release, contact:
Hal Gunn, MDCEOQu Biologics Inc.Phone: 604.734.1450 Email: media@qubiologics.com
Qu Biologics Inc. cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Qu Biologics' forward-looking statements due to the risks and uncertainties inherent in Qu Biologics' business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Qu Biologics does not assume any obligation to update any forward-looking statements except as required by law.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
21 hours ago
- Yahoo
TELUS Health for Good™ and Victoria Cool Aid Society launch series of hepatitis C testing events in Victoria
In recognition of World Hepatitis Day, TELUS and Victoria Cool Aid Society support life-saving screening for high-risk populations VICTORIA, BC, July 24, 2025 /CNW/ - Today, Victoria Cool Aid Society and TELUS Health for Good launched a series of hepatitis C testing events enabled through the two Cool Aid Mobile Health Clinics powered by TELUS Health. Today's event takes place at Victoria's largest shelter, Rock Bay Landing, with Cool Aid staff on site delivering hepatitis C rapid testing and TELUS volunteers providing nutritional support, helping to facilitate access to essential health services. With additional events planned throughout the remainder of the year, this collaboration will enable Cool Aid to reach their goal of completing 700 hepatitis C tests in 2025. "Hepatitis C often has no symptoms, so you could have it without knowing," said Tamara Barnett, Hepatitis C Program Coordinator, Cool Aid Community Health Centre. "Getting tested helps you start treatment early, avoid liver damage, and prevents passing the virus on to others. Our peer-led testing program has screened over 1,900 people to date, leading to over 50 successful treatments. This support from TELUS will allow us to test more people than ever this year." "At TELUS, we are driven by our collective desire to leverage technology and human compassion to enable better health outcomes for vulnerable populations," said Nimmi Kanji, Executive Director TELUS Friendly Future Foundation and TELUS Social Purpose Programs. "Through our longstanding partnership with Victoria Cool Aid Society, we are enabling access to life-saving hepatitis C testing directly to those facing significant barriers to accessing traditional healthcare. By combining our mobile health technology with community-based care, we are ensuring that early detection and treatment is accessible to those who need it most, helping create a healthier, more inclusive future for all." Hepatitis C is an infection of the liver that, if left untreated, can lead to serious health problems including liver damage, cirrhosis, and liver cancer. With no vaccine available and more than 50 million people affected worldwide, including approximately 200,000 Canadians, early detection and treatment can be life-saving. According to studies, the prevalence of hepatitis C can be 10 times higher among people experiencing housing instability compared to the overall population. Fortunately, the testing process is quick, easy, and accurate, with treatment curing 95 per cent of people within 8 to 12 weeks. Building on decades of primary healthcare and social support services, the two Cool Aid Mobile Health Clinics powered by TELUS Health have supported more than 40,000 patient visits across Greater Victoria since their respective launches in 2021 and 2023. In addition to point-of-care testing, the mobile clinics also provide wound care, STI treatment, harm reduction, outreach, and mental health care services to Victorians in need. Additional hepatitis C testing events will take place at community locations across Victoria throughout the remainder of 2025, with dates and locations to be announced shortly. To learn more about TELUS Health for Good, visit About TELUS Health for Good Since 2014, TELUS Health for Good has been connecting underserved individuals to the medical and mental health care they need using the power of technology. Backed by a commitment of $16 million through 2027, TELUS Mobile Health Clinics have now supported over 300,000 patient visits across 27 Canadian communities since inception. Equipped with TELUS electronic medical records technology, and fuelled by compassion, our Mobile Health Clinics provide essential primary medical care to individuals living on the streets. The program also supports caregivers experiencing marginalization with access to free TELUS Health MyCare Counselling sessions and supports low-income older adults to live more independently and enjoy peace of mind with low-cost TELUS Health Medical Alert services. To learn more about TELUS Health for Good, visit About TELUS TELUS (TSX: T, NYSE: TU) is a world-leading communications technology company operating in more than 45 countries and generating over $20 billion in annual revenue with more than 20 million customer connections through our advanced suite of broadband services for consumers, businesses and the public sector. We are committed to leveraging our technology to enable remarkable human outcomes. TELUS is passionate about putting our customers and communities first, leading the way globally in client service excellence and social capitalism. Our TELUS Health business is enhancing more than 150 million lives across 200 countries and territories through innovative preventive medicine and well-being technologies. Our TELUS Agriculture & Consumer Goods business utilizes digital technologies and data insights to optimize the connection between producers and consumers. Guided by our enduring 'give where we live' philosophy, TELUS, our team members and retirees have contributed $1.8 billion in cash, in-kind contributions, time and programs including 2.4 million days of service since 2000, earning us the distinction of the world's most giving company. We're always building Canada. For more information, visit or follow @TELUSNews on X and @Darren_Entwistle on Instagram. About the Victoria Cool Aid Society The Victoria Cool Aid Society believes that everyone deserves home, health and community. We create opportunities for people who are experiencing homelessness or living in poverty and we make a difference through housing, health and dental care, community, and emergency shelters. Founded in 1968, Cool Aid helps more than 12,000 people in the Capital region every year, at 20 locations in Victoria, Saanich and Langford, including more than 7,000 Community Health Centre patients. For more information about Cool Aid, visit For media inquiries, please contact: Saara RahikkaTELUS Media Relations SOURCE TELUS Communications Inc. View original content to download multimedia: Sign in to access your portfolio
Yahoo
a day ago
- Yahoo
Researchers make astonishing discovery that could reshape $900 million food sector: 'This breakthrough is incredibly important'
Researchers make astonishing discovery that could reshape $900 million food sector: 'This breakthrough is incredibly important' Scientists have made an exciting discovery that could transform your daily breakfast meal. According to for the first time ever, researchers from McGill University have altered oat DNA with great success. By editing oat DNA, scientists have the potential to produce oats that are not only richer in fiber but also more resilient to rising global temperatures. Published in Plant Biotechnology Journal, the study reveals how the scientists used a type of gene-cutting method — which, until now, had never been used on oats. Known as CRISPR-Cas9 gene-editing technology, the process essentially cuts out and alters specific pieces of the oat's genes. Applying this gene-cutting technology to oat production is a game-changer. "Using CRISPR-Cas9, we were able to make very specific genetic changes in oats that would traditionally take years to achieve through conventional breeding," said study leader and plant sciences professor Jaswinder Singh, per "Our method not only speeds up the breeding process but also allows us to avoid introducing foreign DNA into the plants, making them safer and more acceptable to consumers." In Canada, the oat crop plays a significant economic role, with an estimated worth of about $900 million, reported. However, unstable weather along with a short growing season has made the staple crop vulnerable. As the researchers examined different changes in the oats' genetic makeup and the impact of those changes, they were able to identify which genes influenced specific traits. For example, the team was able to discover oat plants with altered flowering times. "This breakthrough is incredibly important for climate adaptation," said Ph.D. student Mehtab Singh, lead author of the paper, per "By developing oats that mature earlier or can handle colder conditions, we're helping farmers in regions with short growing seasons or unpredictable weather patterns grow more reliable and sustainable crops." Strengthening oat as a crop will help protect the global food supply and safeguard communities from climate-driven food shortages. Across the globe, farmers have struggled to yield successful harvests due to extreme weather and rising global temperatures. However, by adapting crops at the genetic level, scientists can help farmers produce healthy harvests. From an environmental standpoint, faster-maturing oats have numerous benefits, according to the researchers. Genetically modifying oats to mature faster reduces the need for conventional speed-up techniques that rely on harsh chemicals. Moving forward, the researchers are excited to explore other genetic traits in oats, including disease resistance and stress tolerance. What single change would make the biggest dent in your personal food waste? Not buying food I don't need Freezing my food before it goes bad Using my leftovers more effectively Composting my food scraps Click your choice to see results and speak your mind. Join our free newsletter for easy tips to save more and waste less, and don't miss this cool list of easy ways to help yourself while helping the planet. Solve the daily Crossword
Yahoo
a day ago
- Yahoo
Pura Scents recalling more than 850,000 diffusers as magnet issue may cause ingestion hazard
Pura Scents is recalling more than 850,000 diffusers because some magnets may detach and cause a possible ingestion hazard to children. The company is recalling about 851,400 Pura 4 Smart Home Fragrance Diffusers with detachable covers. It said an additional 1,100 were sold in Canada. Pura Scents said that the magnets on the inside cover of the product can detach, posing an ingestion hazard to children. When high-powered magnets are swallowed, the ingested magnets can attract each other, or other metal objects, and become lodged in the digestive system. This can result in perforations, twisting or blockage of the intestines, infection, blood poisoning and death. The company has received three reports of magnets detaching from the cover. No injuries have been reported. The diffusers were sold at Target, Scheels and other stores nationwide from August 2023 through May 2025 for about $50. They were also sold online through Pura's website, as well as online at Amazon, Target and Scheels. Pura Scents is offering a free replacement cover. Consumers are advised to immediately dispose of the existing detachable cover and to keep the diffusers out of the reach of children and pets. To receive the free replacement cover, individuals may contact Pura Scents at 855-394-5292 from 9 a.m. to 5 p.m. MT Monday through Friday. The company can also be emailed at replacement@ Consumers may also visit the company's website and click on 'Recall' at the bottom of the page for more information. Michelle Chapman, The Associated Press Sign in to access your portfolio
